GB0420970D0 - Novel triazoloquinoline compounds - Google Patents

Novel triazoloquinoline compounds

Info

Publication number
GB0420970D0
GB0420970D0 GB0420970A GB0420970A GB0420970D0 GB 0420970 D0 GB0420970 D0 GB 0420970D0 GB 0420970 A GB0420970 A GB 0420970A GB 0420970 A GB0420970 A GB 0420970A GB 0420970 D0 GB0420970 D0 GB 0420970D0
Authority
GB
United Kingdom
Prior art keywords
triazoloquinoline
novel
compounds
triazoloquinoline compounds
novel triazoloquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0420970A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to GB0420970A priority Critical patent/GB0420970D0/en
Publication of GB0420970D0 publication Critical patent/GB0420970D0/en
Priority to PE2005001075A priority patent/PE20060818A1/en
Priority to PCT/EP2005/010177 priority patent/WO2006032470A1/en
Priority to TW094132221A priority patent/TW200621772A/en
Priority to ARP050103899A priority patent/AR051089A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB0420970A 2004-09-21 2004-09-21 Novel triazoloquinoline compounds Ceased GB0420970D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB0420970A GB0420970D0 (en) 2004-09-21 2004-09-21 Novel triazoloquinoline compounds
PE2005001075A PE20060818A1 (en) 2004-09-21 2005-09-19 TRIAZOLOQUINOLEIN COMPOUNDS THAT INCREASE APOLIPOPROTEIN A-1 PRODUCTION
PCT/EP2005/010177 WO2006032470A1 (en) 2004-09-21 2005-09-19 Compounds which increase apolipoprotein a-1 production and uses thereof in medicine
TW094132221A TW200621772A (en) 2004-09-21 2005-09-19 Compounds which increase apolipoprotein a-1 production and uses thereof in medicine
ARP050103899A AR051089A1 (en) 2004-09-21 2005-09-20 TRIAZOLOQUINOLEINE AND TRIAZOLONAFTIRIDINE SUBSTITUTED COMPOUNDS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0420970A GB0420970D0 (en) 2004-09-21 2004-09-21 Novel triazoloquinoline compounds

Publications (1)

Publication Number Publication Date
GB0420970D0 true GB0420970D0 (en) 2004-10-20

Family

ID=33306953

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0420970A Ceased GB0420970D0 (en) 2004-09-21 2004-09-21 Novel triazoloquinoline compounds

Country Status (5)

Country Link
AR (1) AR051089A1 (en)
GB (1) GB0420970D0 (en)
PE (1) PE20060818A1 (en)
TW (1) TW200621772A (en)
WO (1) WO2006032470A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572771B1 (en) 2004-10-15 2009-08-11 The United States Of America As Represented By The Departments Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
US7723355B2 (en) * 2006-11-20 2010-05-25 Bristol-Myers Squibb Company 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods
WO2010049103A1 (en) * 2008-10-31 2010-05-06 Eth Zurich Soluble truncated apom proteins and medical uses thereof
EP2456440B1 (en) * 2009-07-22 2015-08-19 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
ME02360B (en) 2009-11-05 2016-06-20 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
KR20120097508A (en) 2009-11-05 2012-09-04 글락소스미스클라인 엘엘씨 Benzodiazepine bromodomain inhibitor
RU2438672C1 (en) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Agent showing properties of cognitive function activator (versions)
JP5844358B2 (en) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー Bromodomain inhibitors containing benzotriazolodiazepine compounds
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
CN104718201A (en) 2012-06-12 2015-06-17 艾伯维公司 Pyridinone and pyridazinone derivatives
AU2014256750B2 (en) 2013-04-26 2018-08-23 Beigene, Ltd. Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
TWI764237B (en) 2016-04-15 2022-05-11 美商艾伯維有限公司 Bromodomain inhibitors
WO2021048852A1 (en) 2019-09-11 2021-03-18 Yeda Research And Development Co. Ltd. Methods of treating breast cancer
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (en) 2021-02-25 2023-01-16 美商英塞特公司 Spirocyclic lactams as jak2 v617f inhibitors
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50116498A (en) * 1974-02-27 1975-09-11
AU2001293847B2 (en) * 2000-10-02 2007-05-24 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds

Also Published As

Publication number Publication date
TW200621772A (en) 2006-07-01
AR051089A1 (en) 2006-12-20
PE20060818A1 (en) 2006-08-16
WO2006032470A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EP1718638A4 (en) Novel compounds
GB0400812D0 (en) Novel compounds
GB0409744D0 (en) Novel compounds
GB0405628D0 (en) Novel compounds
GB0420970D0 (en) Novel triazoloquinoline compounds
GB0402140D0 (en) Novel compounds
GB0402496D0 (en) Novel compounds
EP1805132A4 (en) Novel compounds
EP1796793A4 (en) Novel compounds
GB0402357D0 (en) Novel compounds
GB0402355D0 (en) Novel compounds
GB0402812D0 (en) Novel compounds
GB0402380D0 (en) Novel compounds
GB0404105D0 (en) Novel compounds
GB0400901D0 (en) Novel compounds
GB0402134D0 (en) Novel compounds
GB0420290D0 (en) Novel compounds
GB0411167D0 (en) Novel compounds
GB0400885D0 (en) Novel compounds
GB0408984D0 (en) Novel compounds
GB0400460D0 (en) Novel compounds
GB0400171D0 (en) Novel compounds
GB0408448D0 (en) Novel compounds
GB0404564D0 (en) Novel compounds
GB0401727D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)